Accomplished medicinal chemist and project leader with proven ability to drive projects efficiently from hit identification to clinical development candidates.● Expert knowledge of targeted protein degradation (TPD) technologies● Broad understanding of drug discovery process and pre-clinical development● Demonstrated project management, leadership, communication and negotiation skills.● Expertise in multiple therapeutic areas: Oncology, Ophthalmology, Antiviral, Diabetes● Extensive knowledge in optimization of physicochemical properties, pharmacokinetics, metabolism, and toxicity (ADMET) of drug candidates.●Broad experience managing outsourcing efforts to foreign (Asian, European) CROs.●Certified Project Management Professional (PMP)Recent publications:Le P.T, Cheng, H.; Ninkovic,S.; Plewe, M., et. al. Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Ka and mTOR. Biorg. Med. Chem. Lett. 2012, 22, 5098–5103.Plewe, M. B., Johnson, T. W, Azaindole Hydroxamic Acids are HIV Integrase Inhibitors. In: HIV-1 Integrase, Mechanism and Inhibitor Design, N. Neamati, Ed.; Wiley: Hoboken, 2011, 265 – 274.Johnson, T. W. ; Tanis, S. P.; Plewe, M. B et al. Design and Synthesis of N-Hydroxy-Dihydronaphthyridinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors. J. Med. Chem. 2011, 54, 3393 – 3417.Tanis, S. P.; Plewe, M. B.; Johnson, T. W. et al., Azaindole N-Methyl Hydroxamic Acids as HIV Integrase Inhibitors - II. The Impact of Physicochemical Properties on ADME and PK. Biorg. Med. Chem. Lett. 2010, 20, 7429 - 7434.Specialties: targeted protein degradation, E3-ligases, PROTAC, drug discovery, medicinal chemistry, project management, oncology, antivirals, ophthalmology, virtual screening, structure-based-drug-design (SBDD), hit-to-lead, lead development, ADMET, databases (Scifinder, Reaxys), Spotfire, patents, outsourcing.